Goldman Sachs
LENZ

Goldman Sachs’s LENZ Therapeutics LENZ Stock Holding History

Goldman Sachs’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$856K Sell
150,659
-33,097
-18% -$267K ﹤0.01% 5348
2026
Q1 		$1.68M Sell
183,756
-74,186
-29% -$1.04M ﹤0.01% 4682
2025
Q4 		$4.13M Buy
257,942
+216,666
+525% +$6.32M ﹤0.01% 3924
2025
Q3 		$1.92M Buy
+41,276
New +$1.52M ﹤0.01% 4520
2025
Q2 		– Sell
-22,933
Closed -$590K – 6500
2025
Q1 		$590K Sell
22,933
-26,853
-54% -$661K ﹤0.01% 5086
2024
Q4 		$1.44M Buy
49,786
+16,732
+51% +$510K ﹤0.01% 4561
2024
Q3 		$785K Buy
33,054
+19,831
+150% +$440K ﹤0.01% 4802
2024
Q2 		$229K Buy
+13,223
New +$231K ﹤0.01% 5202
2024
Q1 		– Sell
-4,077
Closed -$74.8K – 5936
2023
Q4 		$74.8K Sell
4,077
-749
-16% -$12.4K ﹤0.01% 5335
2023
Q3 		$83.8K Sell
4,826
-127
-3% -$2.21K ﹤0.01% 5210
2023
Q2 		$90.2K Buy
4,953
+3,070
+163% +$61.3K ﹤0.01% 5375
2023
Q1 		$32.3K Sell
1,883
-2,203
-54% -$35.6K ﹤0.01% 5615
2022
Q4 		$95K Sell
4,086
-31,876
-89% -$739K ﹤0.01% 5489
2022
Q3 		$798K Sell
35,962
-23,764
-40% -$566K ﹤0.01% 4673
2022
Q2 		$1.15M Buy
59,726
+54,399
+1,021% +$1.21M ﹤0.01% 4507
2022
Q1 		$190K Buy
5,327
+2,485
+87% +$155K ﹤0.01% 5909
2021
Q4 		$247K Sell
2,842
-7,745
-73% -$642K ﹤0.01% 5780
2021
Q3 		$1.22M Sell
10,587
-28,617
-73% -$4.24M ﹤0.01% 4599
2021
Q2 		$8.43M Buy
+39,204
New +$6.83M ﹤0.01% 2858

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Goldman Sachs's LENZ Position: Q2 2026 in Review

Goldman Sachs reduced its LENZ Therapeutics (LENZ) stake by 18% in Q2 2026, selling an estimated $267K and leaving 150,659 shares worth $856K. The position accounts for ﹤0.01% of the portfolio, ranked #5348.

Goldman Sachs first reported a position in LENZ in Q2 2021 and has held it in 19 quarters since. The position peaked at $8.43M in Q2 2021. 144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Goldman Sachs held 150,659 shares of LENZ Therapeutics worth $856K as of Q2 2026.
  • Goldman Sachs sold 33,097 LENZ Therapeutics shares in Q2 2026, an estimated $267K.
  • LENZ Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5348 holding.
  • Goldman Sachs first reported a position in LENZ Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • Goldman Sachs's LENZ Therapeutics position peaked at $8.43M in Q2 2021.
  • 144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.